Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Young breast cancer patients forgo tamoxifen over fertility concerns

01 September 2015

By Kirsty Oswald

Appeared in BioNews 817

Researchers in the USA have found that fertility concerns may be contributing to low tamoxifen use and discontinuation of the drug among reproductive-age breast cancer patients.

Tamoxifen is recommended for five years following treatment for certain types of breast cancer. Previous research has shown that the drug reduces the risk of disease recurrence by 47 percent and the risk of death by 26 percent.

While the drug is not thought to damage fertility itself, women must stop taking it if they wish to become pregnant because it is teratogenic.

Researchers Dr Jacqueline Jeruss, from the University of Michigan in Ann Arbor, and colleagues found that 35 percent of patients who either refused to take tamoxifen or discontinued treatment before five years cited fertility concerns as the reason.

'With this information, what we hope we will now be able to accomplish is a targeted intervention that is in line with current guidelines... that state that patients should be referred to a fertility specialist at the earliest possible time point in their diagnosis,' Dr Jeruss told MedPage Today.

In the study, the researchers reviewed the medical notes of 515 premenopausal women with breast cancer for whom tamoxifen was recommended.

They found that, overall, 13 percent of patients declined tamoxifen and a further 16 percent stopped treatment before five years.

The most common reason for refusing or discontinuing tamoxifen was concern or experience of side effects, recorded for 36 and 69 percent of these patients, respectively.

However, the researchers also found that women who expressed at the time of diagnosis that they wanted to preserve their fertility were five times more likely to decline tamoxifen than other women. These women were also 78 percent more likely to discontinue tamoxifen within five years if they did begin taking it.

These findings were also confirmed when then researchers conducted telephone interviews with 88 patients who did not start or discontinued therapy, with 35 percent citing fertility concerns as their primary reason.

'Our study points toward the importance of fertility to young breast cancer patients,' commented Dr Jeruss. 'We need to find a way to bridge the gap between this patient survivorship goal and our concerns as physicians to facilitate the best treatment possible for our patients.'

Currently, women who want to become pregnant while taking tamoxifen are advised to take the treatment for two years before having a break to have a child. However, it is currently unclear what effect that has on the effectiveness of the drug. A large, international trait, known as POSITIVE, is currently underway to attempt to resolve this question.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

04 April 2016 - by Isobel Steer 
A large study has confirmed that modern chemotherapy regimes for childhood cancers can adversely affect both male and female fertility...
26 October 2015 - by Dr Nicoletta Charolidi 
A stem-cell therapy in mice shows promise for reversing infertility in women who have received cancer treatment...
28 September 2015 - by Neil Stoker 
Researchers have identified genetic differences in breast cancers that relapse and those that do not, suggesting that the finding could be used to help doctors identify patients most at risk of their cancer returning...

10 August 2015 - by Dr Rosie Gilchrist 
Adolescents or young adults with cancer may not be aware of available options to preserve their fertility, according to a study published in the journal Cancer...
09 March 2015 - by Meghna Kataria 
A drug can reduce the risk of infertility and early menopause in women undergoing chemotherapy for certain early stage breast cancers...
24 November 2014 - by Isobel Steer 
The majority of young breast cancer patients are not being referred for treatment which could preserve their fertility after chemotherapy, says a UK charity...
22 September 2014 - by Vicky Whitehead 
In the UK, clinical commissioners seem to view the national recommendations on fertility treatment as a sort of à-la-carte menu from which they can pick and choose; altering the definition of a cycle, the age requirements, the number of cycles available, and the access criteria at will...
28 July 2014 - by Ruth Retassie 
Mid Essex Clinical Commissioning Group has proposed to limit access to IVF to cancer patients and HIV-positive men under its options for reform to the funding of its fertility services....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation